Research Perspectives:

Targeting cancer with peptide aptamers

Renaud Seigneuric _, Jessica Gobbo, Pierre Colas and Carmen Garrido

PDF  |  HTML  |  How to cite

Oncotarget. 2011; 2:557-561. https://doi.org/10.18632/oncotarget.297

Metrics: PDF 3042 views  |   HTML 6046 views  |   ?  


Renaud Seigneuric1,2, Jessica Gobbo1,2, Pierre Colas3, Carmen Garrido1,2

1Heat Shock Proteins and Cancer, INSERM, UMR 866 IFR 100, Faculty of Medicine, 7 Boulevard Jeanne D'Arc, 21000 Dijon, France

2Université de Bourgogne, Dijon, France

3CNRS USR 3151, P2I2 Group, Station Biologique, Roscoff, Bretagne, France

Received: June 22, 2011; Accepted: June 24, 2011; Published: June 24, 2011;


Renaud Seigneuric, email:


A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e.g.: antibodies), DNA, RNA but also peptide aptamers are relatively recent agents. Peptide aptamers are seldom described but represent attractive agents that can inhibit a growing panel of oncotargets including Heat Shock Proteins. Potential pitfalls and coming challenges towards successful clinical trials are presented such as optimizing the delivery of peptide aptamers thanks to Nanotechnology.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 297